WO2006017688A3 - Combination therapy using transferrin fusion proteins comprising glp-1 - Google Patents

Combination therapy using transferrin fusion proteins comprising glp-1 Download PDF

Info

Publication number
WO2006017688A3
WO2006017688A3 PCT/US2005/027800 US2005027800W WO2006017688A3 WO 2006017688 A3 WO2006017688 A3 WO 2006017688A3 US 2005027800 W US2005027800 W US 2005027800W WO 2006017688 A3 WO2006017688 A3 WO 2006017688A3
Authority
WO
WIPO (PCT)
Prior art keywords
transferrin fusion
combination therapy
glp
fusion proteins
inhibitors
Prior art date
Application number
PCT/US2005/027800
Other languages
French (fr)
Other versions
WO2006017688A2 (en
Inventor
Homayoun Sadeghi
Christopher Prior
David J Balance
Original Assignee
Biorexis Pharmaceutical Corp
Homayoun Sadeghi
Christopher Prior
David J Balance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2007001424A priority Critical patent/MX2007001424A/en
Priority to EP05782173A priority patent/EP1814599A4/en
Priority to EA200700391A priority patent/EA200700391A1/en
Priority to BRPI0514115-0A priority patent/BRPI0514115A/en
Priority to AU2005271403A priority patent/AU2005271403A1/en
Priority to CA002575756A priority patent/CA2575756A1/en
Priority to AP2007003920A priority patent/AP2007003920A0/en
Priority to JP2007525008A priority patent/JP2008509153A/en
Application filed by Biorexis Pharmaceutical Corp, Homayoun Sadeghi, Christopher Prior, David J Balance filed Critical Biorexis Pharmaceutical Corp
Publication of WO2006017688A2 publication Critical patent/WO2006017688A2/en
Publication of WO2006017688A3 publication Critical patent/WO2006017688A3/en
Priority to IL181108A priority patent/IL181108A0/en
Priority to TNP2007000039A priority patent/TNSN07039A1/en
Priority to NO20071018A priority patent/NO20071018L/en
Priority to GB0703685A priority patent/GB2431583A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

The present invention provides combination therapy comprising transferrin fusion protein and DPP-IV inhibitors and/or neutral endopeptidase (NEP) inhibitors. The transferrin fusion protein comprises therapeutic polypeptides or peptides useful in the treatment of diseases such as diabetes.
PCT/US2005/027800 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1 WO2006017688A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
AP2007003920A AP2007003920A0 (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1
EA200700391A EA200700391A1 (en) 2004-08-03 2005-08-03 COMBINED TREATMENT WITH THE APPLICATION OF TRANSFERRIN SLIP PROTEINS CONTAINING GLP-1
BRPI0514115-0A BRPI0514115A (en) 2004-08-03 2005-08-03 combination therapy employing transferrin fusion proteins comprising glp-1
AU2005271403A AU2005271403A1 (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising GLP-1
CA002575756A CA2575756A1 (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1
MX2007001424A MX2007001424A (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1.
JP2007525008A JP2008509153A (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion protein containing GLP-1
EP05782173A EP1814599A4 (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1
IL181108A IL181108A0 (en) 2004-08-03 2007-02-01 Combination therapy using transferrin fusion proteins comprising glp-1
TNP2007000039A TNSN07039A1 (en) 2004-08-03 2007-02-02 ASSOCIATION THERAPY USING TRANSFERRIN FUSION PROTEINS COMPRISING GLP-1
NO20071018A NO20071018L (en) 2004-08-03 2007-02-22 Combination treatment using fusion proteins comprising GLP-1
GB0703685A GB2431583A (en) 2004-08-03 2007-02-26 Combination therapy using transferrin fusion proteins comprising GLP-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59803104P 2004-08-03 2004-08-03
US60/598,031 2004-08-03

Publications (2)

Publication Number Publication Date
WO2006017688A2 WO2006017688A2 (en) 2006-02-16
WO2006017688A3 true WO2006017688A3 (en) 2006-08-03

Family

ID=35839920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027800 WO2006017688A2 (en) 2004-08-03 2005-08-03 Combination therapy using transferrin fusion proteins comprising glp-1

Country Status (19)

Country Link
EP (1) EP1814599A4 (en)
JP (1) JP2008509153A (en)
KR (1) KR20070085224A (en)
CN (1) CN101035568A (en)
AP (1) AP2007003920A0 (en)
AU (1) AU2005271403A1 (en)
BR (1) BRPI0514115A (en)
CA (1) CA2575756A1 (en)
CR (1) CR8954A (en)
EA (1) EA200700391A1 (en)
GB (1) GB2431583A (en)
IL (1) IL181108A0 (en)
MA (1) MA28843B1 (en)
MX (1) MX2007001424A (en)
NO (1) NO20071018L (en)
RU (1) RU2007107808A (en)
TN (1) TNSN07039A1 (en)
WO (1) WO2006017688A2 (en)
ZA (1) ZA200701484B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
ES2385934T3 (en) 2004-08-20 2012-08-03 Mannkind Corporation CATALYSIS OF THE SYNTHESIS OF DICETOPIPERAZINA.
KR101644250B1 (en) 2004-08-23 2016-07-29 맨카인드 코포레이션 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
CA2599723A1 (en) * 2005-03-04 2006-09-14 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
DK1928423T3 (en) 2005-09-14 2016-02-29 Mannkind Corp A method for drug formulation based on increasing the affinity of the active substances to the crystalline microparticle surfaces
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20090186817A1 (en) * 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
AU2007278994B2 (en) * 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
WO2008033395A2 (en) * 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
AU2009257311B2 (en) 2008-06-13 2014-12-04 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
TWI532497B (en) 2008-08-11 2016-05-11 曼凱公司 Use of ultrarapid acting insulin
JP5667095B2 (en) 2009-03-11 2015-02-12 マンカインド コーポレイション Apparatus, system and method for measuring inhaler resistance
CA2764505C (en) 2009-06-12 2018-09-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
RU2571331C1 (en) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Systems and methods for dry powder drug delivery
JP5688718B2 (en) * 2010-08-27 2015-03-25 国立大学法人 宮崎大学 Hemokinin-1 receptor and hemokinin-1-derived peptide
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
RU2477726C1 (en) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
CN103160565A (en) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 Research for influence on endocytosis of cell transferrins of UNC-51 kinase
US9809641B2 (en) 2012-04-23 2017-11-07 Nrl Pharma, Inc. Lactoferrin fusion protein and method for preparation thereof
US9802012B2 (en) 2012-07-12 2017-10-31 Mannkind Corporation Dry powder drug delivery system and methods
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
LT2934568T (en) 2012-12-21 2018-02-12 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
ES2754388T3 (en) 2013-03-15 2020-04-17 Mannkind Corp Compositions and methods of microcrystalline dicetopiperazine
CN103275177B (en) * 2013-06-24 2015-08-12 南京财经大学 There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
CN111388680B (en) * 2015-01-28 2024-01-05 中国科学院天津工业生物技术研究所 Application of polypeptide complex as polypeptide or protein drug carrier, method and fusion protein complex thereof
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
WO2018079702A1 (en) 2016-10-28 2018-05-03 株式会社Ｎｒｌファーマ Lactoferrin/albumin fusion protein and production method therefor
WO2019014552A1 (en) * 2017-07-14 2019-01-17 University Of Southern California Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
ES2929416T3 (en) * 2018-06-21 2022-11-29 Novo Nordisk As New compounds for the treatment of obesity
CN110218259B (en) * 2019-06-24 2022-09-16 王跃驹 Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules
CN112661862B (en) * 2020-12-25 2023-03-31 深圳大学 Fusion protein and preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US20020156036A1 (en) * 2000-09-06 2002-10-24 Nicolau Yves Claude Methods and compositions for diseases associated with amyloidosis
US20030138404A1 (en) * 1995-07-14 2003-07-24 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
AU2003270009A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
JP4873860B2 (en) * 2002-08-30 2012-02-08 バイオレクシス ファーマシューティカル コーポレーション Modified transferrin fusion protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030138404A1 (en) * 1995-07-14 2003-07-24 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US20020156036A1 (en) * 2000-09-06 2002-10-24 Nicolau Yves Claude Methods and compositions for diseases associated with amyloidosis
US20030221201A1 (en) * 2001-08-30 2003-11-27 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents

Also Published As

Publication number Publication date
ZA200701484B (en) 2008-07-30
RU2007107808A (en) 2008-09-10
TNSN07039A1 (en) 2008-06-02
EP1814599A2 (en) 2007-08-08
KR20070085224A (en) 2007-08-27
NO20071018L (en) 2007-04-11
EP1814599A4 (en) 2008-12-17
WO2006017688A2 (en) 2006-02-16
CA2575756A1 (en) 2006-02-16
CN101035568A (en) 2007-09-12
GB0703685D0 (en) 2007-04-04
GB2431583A (en) 2007-05-02
MA28843B1 (en) 2007-09-03
CR8954A (en) 2007-10-02
AU2005271403A1 (en) 2006-02-16
EA200700391A1 (en) 2007-10-26
AP2007003920A0 (en) 2007-02-28
IL181108A0 (en) 2007-07-04
MX2007001424A (en) 2008-03-13
JP2008509153A (en) 2008-03-27
BRPI0514115A (en) 2008-05-27

Similar Documents

Publication Publication Date Title
WO2006017688A3 (en) Combination therapy using transferrin fusion proteins comprising glp-1
GEP20105111B (en) Rage fusion proteins and methods of use
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
WO2005067601A3 (en) Vectors for recombinant protein expression in e.coli
WO2007064917A3 (en) Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
WO2005047327A8 (en) NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
AU2003228962A1 (en) Ferritin fusion proteins for use in vaccines and other applications
WO2007091250A8 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2006074390A3 (en) Methods of treating obesity with combination therapeautics of igf-i fusion polypeptides
IL177049A0 (en) Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
WO2006041641A3 (en) Therapeutic agents with decreased toxicity
WO2006023359A3 (en) Selective vpac2 receptor peptide agonists
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2008060634A3 (en) Human complement c3 derivatives with cobra venom factor-like function
WO2005051902A8 (en) Modified mscl protein channel
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2007018879A3 (en) Interferon-gamma antagonists and therapeutic uses thereof
WO2007143161A3 (en) Use of proteins and peptides of the tgf-beta superfamily for purification and therapeutic methods
EP2096120A3 (en) Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2006138610A3 (en) Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof
WO2005000891A3 (en) Thrombopoietin proteins with improved properties
WO2007002739A3 (en) Chromium-amino acid complexes in the treatment of diabetes and other diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2575756

Country of ref document: CA

Ref document number: 2005271403

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 181108

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/001424

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: DZP2007000092

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007525008

Country of ref document: JP

Ref document number: 12007500315

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/003920

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2007/01484

Country of ref document: ZA

Ref document number: 200701484

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005271403

Country of ref document: AU

Date of ref document: 20050803

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005271403

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 0703685

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20050803

WWE Wipo information: entry into national phase

Ref document number: 0703685.8

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 2005782173

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 553501

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 760/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 9906

Country of ref document: GE

Ref document number: 07021337

Country of ref document: CO

Ref document number: 1200700477

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2007107808

Country of ref document: RU

Ref document number: 1020077005257

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200700391

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 200580033674.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005782173

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0514115

Country of ref document: BR